This study evaluates a target population of patients with Hepatitis C virus (HCV) infection, including those with complications like liver cirrhosis (LC) and hepatocellular carcinoma (HCC), to investigate the diagnostic utility of a specific panel of microRNAs (miRNAs). The intervention involves quantifying the plasma expression (PE) levels of MiR-21, 1246, 205, 29a-3p, and 497 via PCR and comparing them to healthy controls to determine their efficacy as biomarkers. The primary outcome is to assess the sensitivity, specificity, and overall accuracy of these miRNAs in differentiating HCC from cirrhotic and non-cirrhotic HCV cases, aiming to establish more reliable screening tools than current standard biomarkers like alpha-fetoprotein (AFP).
Study Type
OBSERVATIONAL
Enrollment
84
PCR quantification of plasma microRNA levels (MiR-21, 1246, 205, 29a-3p, and 497).
Alexandria Faculty of medicine
Alexandria, El Alexandria, Egypt
Success Rate of Diagnostic Regimens in Identifying Hepatocellular Carcinoma
iagnostic utility (sensitivity, specificity, and accuracy rate) of estimated plasma expression (PE) levels of microRNAs (specifically Mir-1246, Mir-21, and Mir-497) to distinguish HCC from LC and HCV
Time frame: Around 3 months
Diagnostic Performance for LC
Differentiating liver cirrhosis using downregulated MiR-205 and overexpressed MiR-29a.
Time frame: Around 3 months
Biomarker Correlation
Correlation between miRNA levels and serum Alpha-Fetoprotein (AFP).
Time frame: Around 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.